Page 56 - AN-2-2

Advanced Neurology Seizures and CKD

74. Hitchings AW, 2016, Drugs that lower the seizure threshold. 86. Tan TC, Robinson PJ, 2006, Mechanisms of calcineurin
Adverse Drug React Bull, 298: 1151–1154. inhibitor-induced neurotoxicity. Transplant Rev, 20: 49–60.
https://doi.org/10.1097/FAD.0000000000000016 https://doi.org/10.1016/j.trre.2006.02.005
75. Sahani MM, Daoud TM, Sam R, et al., 2001, Dialysis 87. Anghel D, Tanasescu R, Campeanu A, et al., 2013,
disequilibrium syndrome revisited. Hemodial Int, 5: 92–96. Neurotoxicity of immunosuppressive therapies in organ
transplantation. Maedica, 8: 170–175.
https://doi.org/10.1111/hdi.2001.5.1.92
88. De Castro JT, Appenzeller S, Colella MP, et al., 2022,
76. Mistry K, 2019, Dialysis disequilibrium syndrome Neurological manifestations in thrombotic microangiopathy:
prevention and management. Int J Nephrol Renovasc Dis, Imaging features, risk factors and clinical course. PLoS One,
12: 69–77.
17: e0272290.
https://doi.org/10.2147/IJNRD.S165925
https://doi.org/10.1371/journal.pone.0272290
77. Zepeda-Orozco D, Quigley R, 2012, Dialysis disequilibrium 89. Mohammadi MH, Salarzaei M, Parooie F, 2019, Neurological
syndrome. Pediatr Nephrol, 27: 2205–2211.
complications after renal transplantation: A systematic
https://doi.org/10.1007/s00467-012-2199-4 review and meta‐analysis. Ther Aph Dial, 23: 518–528.
78. Trinh-Trang-Tan MM, Cartron JP, Bankir L, 2005, https://doi.org/10.1111/1744-9987.12838
Molecular basis for the dialysis disequilibrium syndrome: 90. Faravelli I, Velardo D, Podestà MA, et al., 2021,
Altered aquaporin and urea transporter expression in the Immunosuppression-related neurological disorders in
brain. Nephrol Dial Transplant, 20: 1984–1988. kidney transplantation. J Nephrol, 34: 539–555.
https://doi.org/10.1093/ndt/gfh877 https://doi.org/10.1007/s40620-020-00956-1
79. Wong SS, Kwaan HC, Ing TS, 2017, Venous air embolism 91. Bayer G, von Tokarski F, Thoreau B, et al., 2019, Etiology and
related to the use of central catheters revisited: With outcomes of thrombotic microangiopathies. Clin J Am Soc
emphasis on dialysis catheters. Clin Kidney J, 10: 797–803. Nephrol, 14: 557–566.
https://doi.org/10.1093/ckj/sfx064 https://doi.org/10.2215/CJN.11470918
80. Brull SJ, Prielipp RC, 2017, Vascular air embolism: A silent 92. Sakhuja V, Sud K, Kalra OP, et al., 2001, Central nervous
hazard to patient safety. J Crit Care, 42: 255–263. system complications in renal transplant recipients in a
https://doi.org/10.1016/j.jcrc.2017.08.010 tropical environment. J Neurol Sci, 183: 89–93.
81. Sprague SM, Corwin HL, Wilson RS, et al., 1986, https://doi.org/10.1016/s0022-510x(00)00485-8
Encephalopathy in chronic renal failure responsive to 93. Mahale P, Shiels MS, Lynch CF, et al., 2018, Incidence and
deferoxamine therapy: Another manifestation of aluminum outcomes of primary central nervous system lymphoma
neurotoxicity. Arch Intern Med, 146: 2063–2064. in solid organ transplant recipients. Am J Transplant,
https://doi.org/10.1001/archinte.1986.00360220245039 18: 453–461.
82. Coulson JM, Hughes BW, 2022, Dose-response relationships https://doi.org/10.1111/ajt.14465
in aluminum toxicity in humans. Clin Toxicol, 60: 415–428. 94. Snanoudj R, Durrbach A, Leblond V, et al., 2003, Primary
https://doi.org/10.1080/15563650.2022.2029879 brain lymphomas after kidney transplantation: Presentation
and outcome. Transplantation, 76: 930–937.
83. Sadakane Y, Kawahara M, 2018, Implications of metal
binding and asparagine deamidation for amyloid formation. https://doi.org/10.1097/01.TP.0000079253.06061.52
Int J Mol Sci, 19: 2449. 95. DeAngelis LM, 1999, Primary central nervous system
https://doi.org/10.3390/ijms19082449 lymphoma. J Neurol Neurosurg Psychiatry, 66: 699–701.
84. Ahmed GA, Khalil SK, Abbas L, et al., 2020, ATR-IR and https://doi.org/10.1136/jnnp.66.6.699
EPR spectroscopy for detecting the alterations in cortical 96. Power A, Chan K, Singh SK, et al., 2012, Appraising stroke
synaptosomes induced by aluminium stress. Spectrochim risk in maintenance hemodialysis patients: A large single-
Acta A Mol Biomol Spectrosc, 228: 117535. center cohort study. Am J Kidney Dis, 59: 249–257.
https://doi.org/10.1016/j.chemphyslip.2020.104931 https://doi.org/10.1053/j.ajkd.2011.07.016
85. Bechstein WO, 2000, Neurotoxicity of calcineurin 97. Toyoda K, Ninomiya T, 2014, Stroke and cerebrovascular
inhibitors: Impact and clinical management. Transplant Int, diseases in patients with chronic kidney disease. Lancet
13: 313–326. Neurol, 13: 823–833.
https://doi.org/10.1007/s001470050708 https://doi.org/10.1016/S1474-4422(14)70026-2

https://doi.org/10.36922/an.314
Volume 2 Issue 2 (2023) olume 2 Issue 2 (2023)
30
V 30 https://doi.org/10.36922/an.314